GlassScriptPhysician profile
Sharon A Butcher
NPI 1164630828
$1,771.73
in general payments reported to CMS, 2019-2025
32 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $89.86 · 2021: $224 · 2022: $356 · 2023: $361 · 2024: $311 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $415.55 | 2019-2025 | Liletta |
| Daiichi Sankyo INC. | $188.00 | 2023-2025 | Injectafer |
| Astellas Pharma US INC | $134.88 | 2019-2025 | Veozah, Cresemba, Myrbetriq |
| Pfizer INC. | $117.07 | 2019-2024 | |
| Channel Medsystems, INC. | $83.17 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.44 | 2020-2023 | |
| Exeltis, USA INC. | $79.73 | 2019-2025 | Slynd |
| Organon LLC | $75.04 | 2024-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $72.73 | 2022-2023 | Myosure Tissue Removal Device |
| Medtronic, INC. | $51.32 | 2023-2025 | Truclear, Interstim |
| Pacira Pharmaceuticals Incorporated | $41.86 | 2024 | Exparel |
| Novo Nordisk INC | $35.80 | 2023-2024 | |
| Agile Therapeutics, INC. | $35.75 | 2021-2022 | |
| Boston Scientific Corporation | $33.64 | 2019 | |
| Shield Therapeutics INC | $29.24 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $28.75 | 2022 | |
| Lupin INC. | $25.82 | 2019-2021 | |
| Therapeuticsmd, INC. | $25.39 | 2021 | |
| Seqirus USA INC | $23.77 | 2024 | Flucelvax |
| Mylan Pharmaceuticals INC. | $22.22 | 2019 | |
| Aspira Women'S Health INC | $21.90 | 2021 | |
| Mayne Pharma Commercial LLC | $18.46 | 2021 | |
| Merck Sharp & Dohme LLC | $17.82 | 2023 | Gardasil 9 |
| Coopersurgical, INC. | $15.34 | 2019 | |
| Duchesnay USA Incorporated | $13.43 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.40 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.08 | 2020 | |
| Avion Pharmaceuticals | $12.41 | 2021 | |
| Amgen INC. | $12.26 | 2019 | |
| Evofem Biosciences, INC. | $11.60 | 2021 | |
| Allergan, INC. | $11.50 | 2019 | |
| Millicent US INC | $9.36 | 2024 | Intrarosa, Femring |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Butcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.